Parkman Healthcare Partners LLC Ionis Pharmaceuticals Inc Transaction History

Parkman Healthcare Partners LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$36.45 - $47.7 $736,508 - $963,826	20,206 Added 14.28%	161,705 $7.71 Million
Q1 2024 May 15, 2024	SELL	$42.03 - $53.55 $2.94 Million - $3.74 Million	-69,901 Reduced 33.07%	141,499 $6.13 Million
Q4 2023 Feb 14, 2024	BUY	$43.39 - $51.63 $2.25 Million - $2.68 Million	51,897 Added 32.54%	211,400 $10.7 Million
Q3 2023 Nov 14, 2023	BUY	$38.5 - $47.13 $248,363 - $304,035	6,451 Added 4.21%	159,503 $7.24 Million
Q2 2023 Aug 11, 2023	BUY	$34.73 - $43.33 $65,674 - $81,937	1,891 Added 1.25%	153,052 $6.28 Million
Q1 2023 May 12, 2023	BUY	$33.58 - $41.2 $337,344 - $413,895	10,046 Added 7.12%	151,161 $5.4 Million
Q4 2022 Feb 13, 2023	SELL	$37.12 - $46.52 $3.74 Million - $4.69 Million	-100,830 Reduced 41.67%	141,115 $5.33 Million
Q3 2022 Nov 14, 2022	BUY	$36.54 - $48.66 $2.47 Million - $3.29 Million	67,645 Added 38.81%	241,945 $10.7 Million
Q2 2022 Aug 12, 2022	BUY	$31.71 - $43.0 $5.53 Million - $7.49 Million	174,300 New	174,300 $6.45 Million
Q1 2022 May 13, 2022	SELL	$29.88 - $37.04 $2.4 Million - $2.97 Million	-80,238 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$25.61 - $35.1 $1.44 Million - $1.97 Million	-56,142 Reduced 41.17%	80,238 $2.44 Million
Q2 2021 Aug 13, 2021	BUY	$34.54 - $47.25 $1.06 Million - $1.45 Million	30,583 Added 28.91%	136,380 $5.44 Million
Q1 2021 May 14, 2021	BUY	$42.51 - $63.78 $1.29 Million - $1.94 Million	30,379 Added 40.28%	105,797 $4.76 Million
Q4 2020 Feb 12, 2021	BUY	$45.3 - $60.27 $3.42 Million - $4.55 Million	75,418 New	75,418 $4.26 Million

403

136M

862K

582K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.35B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Parkman Healthcare Partners LLC with notifications on news.